Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor: Results from the TRANSFORM Study

被引：1

作者：

Oppenheimer, Federico ^{[1
]}

Russ, Graeme ^{[2
]}

Viklicky, Ondrej ^{[3
]}

Oberbauer, Rainer ^{[4
]}

Garcia, Valter ^{[5
]}

Witzke, Oliver ^{[6
]}

Kuypers, Dirk ^{[7
]}

Danguilan, Romina ^{[8
]}

Das Gupta, Ayan ^{[9
]}

Bernhardt, Peter ^{[10
]}

Sommerer, Claudia ^{[11
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Royal Adelaide Hosp, Adelaide, SA, Australia

[3] IKEM, Prague, Czech Republic

[4] Med Univ Vienna, Vienna, Austria

[5] Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil

[6] Univ Klinikum Essen, Essen, Germany

[7] Gasthuisberg Univ Hosp, Leuven, Belgium

[8] Natl Kidney & Transplant Inst, Quezon City, Philippines

[9] Novartis Healthcare Pvt Ltd, Hyderabad, India

[10] Novartis Pharma AG, Basel, Switzerland

[11] Univ Klinikum Heidelberg, Heidelberg, Germany

来源：

TRANSPLANTATION | 2018年 / 102卷

关键词：

D O I：

10.1097/01.tp.0000543112.91427.9d

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

591.2

引用

页码：S363 / S363

页数：1

共 50 条

[31] Clinical Experience of Late Conversion From Antimetabolites With Standard Exposure Calcineurin Inhibitors to Everolimus With Calcineurin Inhibitor Minimization in Stable Kidney Transplant Recipients With Good Renal Function
Uchida, J.
Iwai, T.
Kuwabara, N.
Kabei, K.
Nishide, S.
Yamasaki, T.
Naganuma, T.
Kumada, N.
Takemoto, Y.
Nakatanti, T.
TRANSPLANTATION PROCEEDINGS, 2016, 48 (03) : 775 - 780
[32] Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients
Silva, H. Tedesco, Jr.
Cibrik, D.
Johnston, T.
Lackova, E.
Mange, K.
Panis, C.
Walker, R.
Wang, Z.
Zibari, G.
Kim, Y. S.
AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (06) : 1401 - 1413
[33] Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study
Citterio, Franco
Henry, Mitchell
Kim, Dean Y.
Kim, Myoung Soo
Han, Duck-Jong
Kenmochi, Takashi
Mor, Eytan
Tisone, Giuseppe
Bernhardt, Peter
Gutierrez, Maria Pilar Hernandez
Watarai, Yoshihiko
EXPERT OPINION ON DRUG SAFETY, 2020, 19 (10) : 1339 - 1348
[34] RENAL FUNCTION IN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM TREATED DE NOVO RENAL TRANSPLANT RECIPIENTS AFTER CALCINEURIN INHIBITOR WITHDRAWAL: THE ZEUS STUDY
Becker, T.
Arns, W.
Budde, K.
Eisenberger, U.
Fischer, W.
Kramer, S.
Reinke, P.
Sommerer, C.
Pietruck, F.
TRANSPLANT INTERNATIONAL, 2009, 22 : 78 - 79
[35] Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study.
Mulgaonkar, S.
Qazi, Y.
Kim, D.
Peddi, V.
McCague, K.
Patel, D.
Wiseman, A.
AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 259 - 259
[36] Effect of De Novo Use of Everolimus with Reduced Calcineurin Inhibitor versus Standard Mycophenolic Acid-Based Regimen on Wound Healing Events in Kidney Transplant Recipients from TRANSFORM Study.
Henry, M.
Citterio, F.
Kim, M.
Kim, D.
Bernhardt, P.
Gupta, A.
Watarai, Y.
AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 790 - 790
[37] Sotrastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients
Tedesco-Silva, H.
Kho, M. M. L.
Hartmann, A.
Vitko, S.
Russ, G.
Rostaing, L.
Budde, K.
Campistol, J. M.
Eris, J.
Krishnan, I.
Gopalakrishnan, U.
Klupp, J.
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (07) : 1757 - 1768
[38] Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study (vol 103, pg 1953, 2019)
Tedesco-Silva
TRANSPLANTATION, 2020, 104 (05) : E142 - E142
[39] EFFICACY AND SAFETY OF EVEROLIMUS [EVR] WITH REDUCED-DOSE CALCINEURIN INHIBITOR [RCNI] IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS [KTXRS]: M24 RESULTS FROM THE TRANSFORM STUDY
Legendre, C.
Chadban, S.
Tedesco, H.
Berger, S.
Qazi, Y.
Cruzado, J. M.
Bernhardt, P.
Kim, M. S.
Vincenti, F.
Gharbi, H.
Pascual, J.
TRANSPLANT INTERNATIONAL, 2019, 32 : 18 - 19
[40] Optimizing Renal Function through Minimizing Calcineurin Inhibitor Exposure - Long term Results from a Calcineurin Inhibitor-Everolimus Based Immunosuppression
Zweytick, B.
Ghanim, B.
Sillipp, J.
Boehmig, G.
Jaksch, P.
Klepetko, W.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (02): : S15 - S16

← 1 2 3 4 5 →